Topical immunotherapy for skin disease

References

• Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med.356, 580–592 (2007).
   PubMed Web of Science ®Google Scholar
• Sauder DN, Mofid MZ. Topical immunotherapy: what’s new. Dermatol. Clin.23, 245–258 (2005).
   PubMedGoogle Scholar
• Sulzberger MB, Witten VH, Smith CC. Hydrocortisone (compound F) free alcohol ointment. J. Am. Med. Assoc.152, 1456 (1953).
   PubMed Web of Science ®Google Scholar
• Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur. J. Dermatol.13, 455–461 (2003).
   PubMed Web of Science ®Google Scholar
• Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol.45, 736–743 (2001).
   PubMed Web of Science ®Google Scholar
• Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol.10, 230–234 (1997).
   PubMedGoogle Scholar
• Reitamo S, Remitz A, Kyllonen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am. J. Clin. Dermatol.3, 381–388 (2002).
   PubMedGoogle Scholar
• Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr. Allergy Asthma Rep.6, 270–274 (2006).
   PubMed Web of Science ®Google Scholar
• Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol.127, 808–816 (2007).
   PubMed Web of Science ®Google Scholar
• Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch. Dermatol.143, 472–476 (2007).
   PubMed Web of Science ®Google Scholar
• Beltrani VS. Suggestions regarding a more appropriate understanding of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol.5, 413–418 (2005).
   PubMed Web of Science ®Google Scholar
• Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J. Am. Acad. Dermatol.55, 168–1670 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med.336, 1066–1071 (1997).
   PubMed Web of Science ®Google Scholar
• Dorn A, Ludwig RJ, Bock A et al. Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J. Invest. Dermatol.127, 846–854 (2007).
   PubMed Web of Science ®Google Scholar
• Pivarcsi A. Toll-like receptor 9-independent suppression of skin inflammation by oligonucleotides. J. Invest. Dermatol.127, 746–748 (2007).
   PubMed Web of Science ®Google Scholar
• Sauder DN The emerging role of immunotherapy in the treatment of non-melanoma skin cancers. Nat. Clin. Pract. Oncol.2, 326–327 (2005).
   PubMedGoogle Scholar
• Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol.149(Suppl. 66), 15–19 (2003).
   PubMed Web of Science ®Google Scholar
• Harwood CA, Perrett CM, Brown VL, Leigh IM, McGregor JM, Proby CM. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br. J. Dermatol.152, 122–129 (2005).
   PubMed Web of Science ®Google Scholar
• Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br. J. Dermatol.149(Suppl. 66), 20–24 (2003).
   PubMed Web of Science ®Google Scholar
• Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol.3, 3011 (2002).
   Google Scholar
• Suzuki H, Wang B, Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol.114, 135–141 (2000).
   PubMed Web of Science ®Google Scholar
• Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs58, 375–390 (1999).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95, 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J. Cutan. Med. Surg.11, 19–30 (2007).
   PubMed Web of Science ®Google Scholar
• Holikova Z, Massi D, Lotti T, Hercogova J. Insight into the pathogenesis of sporadic basal cell carcinoma. Int. J. Dermatol.43, 865–869 (2004).
   PubMedGoogle Scholar
• Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science276, 817–821 (1997).
   PubMed Web of Science ®Google Scholar
• Lear JT, Hoban P, Strange RC, Fryer AA. Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes. Clin. Exp. Dermatol.30, 49–55 (2005).
   PubMedGoogle Scholar
• Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol.50, 722–733 (2004).
   PubMed Web of Science ®Google Scholar
• Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J. Dermatol. Surg. Oncol.15, 315–328 (1989).
   PubMedGoogle Scholar
• Patel GK, Goodwin R, Chawla M et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.54, 1025–1032 (2006).
   PubMed Web of Science ®Google Scholar